Ars Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.41, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Ars Pharmaceuticals Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 107 days, from 106 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 460 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2978, from overall ranking in the first quarter 2026 at 3408.

What is Receivable Turnover Ratio?
What is Ars Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SPRY Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	86.42 %	208.09 %	210.06 %	4615.52 %	-
Y / Y Revenue Change	114.15 %	184.47 %	-67.56 %	1471.62 %	3043.4 %
Receivable Turnover Ratio (TTM)	3.41	3.43	3.5	7.22	10.36
SPRY's Total Ranking	# 2978	# 3408	# 1857	# 1223	# 665
Accounts Receivable average collection period days	107	107	104	51	35
Seq. Receivable Change	63.42 %	13.08 %	-30.46 %	45.07 %	170.08 %
Seq. Revenue Change	48.4 %	-19.25 %	-13.58 %	106.79 %	97.13 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 143
Healthcare Sector	# 461
Overall Market	# 2978

Receivable Turnover Ratio Statistics
High	Average	Low
21.29	8.2	3.41
(Mar 31 2025)		(Jun 30 2026)

SPRY Company Profile • Back to SPRY Efficiency Comparisons • Compare SPRY Receivables Turnover Ratio to its Competitors

Financial Statements
Ars Pharmaceuticals Inc 's Accounts Receivable	$ 47 Millions	Visit SPRY's Balance sheet
Ars Pharmaceuticals Inc 's Sales TTM	$ 117 Millions	Visit SPRY's Income Statement
Sources of SPRY's Revenues		Visit SPRY's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SPRY's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SPRY's Growth Rates	SPRY's Roa	SPRY's Inventory Turnover Ratio	SPRY's Dividend Comparisons
SPRY's Profitability Ratios	SPRY's Roi	SPRY's Asset Turnover Ratio	SPRY's Dividend Growth
SPRY's Valuation Ratios	SPRY's Roe	SPRY's Financial Strength Ratios	SPRY's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Tarsus Pharmaceuticals Inc	6.85	$ 606.331 Millions	$ 88.512 Millions
Neuropace Inc	6.85	$ 98.620 Millions	$ 14.398 Millions
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Delcath Systems Inc	6.77	$ 94.058 Millions	$ 13.899 Millions
Moderna Inc	6.76	$ 2,228.000 Millions	$ 329.500 Millions
Carlisle Companies Incorporated	6.76	$ 5,097.000 Millions	$ 754.025 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Ufp Technologies Inc	6.65	$ 632.042 Millions	$ 94.976 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Livanova Plc	6.62	$ 1,470.112 Millions	$ 222.035 Millions
Agilon Health Inc	6.61	$ 5,920.015 Millions	$ 895.120 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Beone Medicines Ltd	6.58	$ 6,128.238 Millions	$ 930.639 Millions
Embecta Corp	6.57	$ 1,019.700 Millions	$ 155.125 Millions
Editas Medicine Inc	6.57	$ 47.005 Millions	$ 7.156 Millions
Labcorp Holdings Inc	6.49	$ 14,348.000 Millions	$ 2,210.975 Millions
Intellia Therapeutics Inc	6.44	$ 59.506 Millions	$ 9.243 Millions
Cvrx inc	6.44	$ 60.164 Millions	$ 9.345 Millions
Schrodinger Inc	6.43	$ 259.035 Millions	$ 40.267 Millions
Baxter International Inc	6.43	$ 11,555.000 Millions	$ 1,798.000 Millions
Healthcare Services Group Inc	6.42	$ 1,864.594 Millions	$ 290.515 Millions
Verastem Inc	6.42	$ 87.526 Millions	$ 13.640 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.